Antagonistic Interaction CB1-paracetamol

Evaluation of the Interaction of Rimonabant (Antagonist of CB1 Receptor) on the Analgesic Effect of Paracetamol in Intravenous Administration

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00750347

Enrollment

Registered

2008-09-10

Start date

2008-09-30

Completion date

2008-10-31

Last updated

2011-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

pain,, analgesia, Healthy volunteers

Brief summary

Evaluation of an possible inhibiting effect of Rimonabant on the analgesic effect of Paracetamol in healthy volunteers

Detailed description

Double Blind, cross-over, randomized and controlled versus placebo, study in healthy volunteers.

Interventions

DRUGRimonabant and Paracetamol and placebo

evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers * between 18 and 40 years old * written consent given

Exclusion criteria

* Rimonabant or paracetamol hypersensibility * Excessive consumption of alcohol, tobacco, coffee, tea or toxicomania * Concomitant medication * Chronical diseases

Design outcomes

Primary

Measure	Time frame
Pain's threshold with electrical stimulation (Pain Matcher). Pain's threshold with mechanical stimulation (electronical Von Frey).	during electrical stimulation

Secondary

Measure	Time frame
Plasmatic concentration of paracetamol or his metabolite with or without Rimonabant	with or without rimonabant

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026